• 2018.12.02
    ¬P´Á¤é

§K¬ÌÀøªkÂå·R´þ ªZº~¨â±Ð±ÂÀò±M§Q
´ä¤j¾ÇªÌ¡G¯à¡uªv¡¡v»P§_ ¤Uµ²½×À³ÂÔ·V

[2018.12.02] µoªí
ªZº~¬ì§Þ¤j¾Ç±Ð±ÂÅU¼é¦¿¡]¥ª¡^¡B±i¦P¦s¡]¥k¡^±N§K¬ÌÀøªk¥Î©óªvÀø·R´þ¯f¡A¦¨¥\´î¤Ö¨â¦W±wªÌÅ餺HIV¯f¬r¡C¡]ºô¤W¹Ï¤ù¡^

¡i©ú³ø±M°T¡j¬Q¤é¬O¥@¬É·R´þ¯f¤é¡A´ò¥_ªZº~¬ì§Þ¤j¾Ç¨â¦W±Ð±Â¥Î­ì¥»ªvÀøÀù¯gªº§K¬ÌÀøªk¨ÓªvÀø·R´þ¯f¡A¦¨¥\´î¤Ö¨â¦W±wªÌÅ餺ªºHIV¯f¬r¡A¨ÃÀò±o°ê®aª¾ÃѲ£Åv§½µo©ú±M§QÃҮѡC¦³­»´ä¾ÇªÌ«ü¡AÃþ¦ü¹êÅç¦b­»´ä¥ç¦³¶i¦æ¡A¦ý¬O§_¯à°÷¡uªv¡¡v·R´þ¡AÀ³ÂÔ·V¤Uµ²½×¡A¥B¦¨¥»¬Û¹ï©ù¶Q¡C

¦¨¥\´î¤Ö¨â±wªÌHIV¯f¬r¡@¡@

ºî¦X¡m·s¨Ê³ø¡n¤Î¤¤·sºô³ø¹D¡A§K¬ÌÀøªk­ì¥»¬O¥Î©óªvÀøÀù¯g¡AÅý¤HÅé¦Û¨­ªº§K¬Ì¨t²Î±þ·ÀÀù²Ó­M¡A¦ÓªZº~¬ì§Þ¤j¾Ç¥Í©R¬ì¾Ç»P°·±d¾Ç°|ªº±i¦P¦s¡BÅU¼é¦¿¨â¦ì±Ð±Â­ì¥»¥Î¦¹¤èªk¥Î©óªvÀø¦å²G¸~½F¡A´¿À°§U¹L350¦h¦W¦å²G¸~½F±wªÌ¡A·í¤¤90%Å餺Àù²Ó­M³Q±þ¦º¡A¨â¦W±Ð±Â«á±N¨äÀ³¥Î¦bªvÀø·R´þ¯f¤W¡C³oºØ§K¬ÌÀøªkºÙ¬°¡uCAR-T¡v(Chimeric Antigen Receptor T-Cell Immunotherapy¡A´O¦X§Ü­ì¨üÅéT²Ó­M§K¬ÌÀøªk)¡A³q¹L§ï³y±wªÌÅ餺ªºT²Ó­M¡A½á¤©¨äÃѧO§Ü­ìªº¯à¤O¡A¦A¤j¶q°ö¾i¡B¦^¿é¤HÅé¡A¨Ï¨ä¥i¥H±þ·À·P¬VHIVªº²Ó­M¡C

¥Ø«e¡A¨â¦ì±Ð±Â¤w§Q¥Î¸Ó§Þ³NªvÀø¤F¨â¦WHIV±wªÌ¡A¤@¦WªvÀø¤F3­Ó¤ë«á¡AHIV¯f¬r«ü¼Ð¨³³t¤U­°¡F¥t¤@¦WªvÀø¤F9­Ó¤ë¡A¥Ø«eÅ餺¨S¦³µo²{HIV¯f¬r¡C±i¦P¦s±Ð±Âªí¥Ü¡A±qÁ{þH¤W¨Ó»¡¡A¥²¶·3¦~¤£´_µo¡A¤~¯àºÙ¬°¡uªv¡¡v¡A±µ¤U¨Ó·|¹ï±wªÌªø´Á¸ò¶i¡C

´¿À³¥ÎªvÀù

¡u¨S±±¨î¦n·|¦³°Æ§@¥Î¡v

´ä¤j·R´þ¯f¬ã¨s©Ò©Òªø³¯§Ó°¶¹ï¥»³øªí¥Ü¡A¥Ø«e¥¼¦³¨£¨ìªZº~¨â¦W±Ð±Â¦³¬ÛÃö½×¤åµoªí¡A¦b¥¼¨£¨ì¬ì¾Ç¼Æ¾Ú¤§«eÃø¥Hµû½×¡C¦ý¥Lªí¥Ü¡A­»´ä¤]¦³°µ¡uCAR-T¡vªº¦PÃþ¹êÅç¡A½T¹ê¯à°÷À£¨îHIV¯f¬rªº½Æ»s¡A¡u¦ý¦pªG»¡¯à¤£¯à°÷ªv¡¡A§Ú»{¬°¤U³o­Óµ²½×­nÂÔ·V¡C¡v³¯«ü¥X¡AÃøÂI¦b©ó¡uCAR-T¡v²Ó­MÃѧO¥Ø¼Ðªº±Ó·P«×¡A§Y¦p¦óÅý¨ä¥u±þ¦º±a¯f¬rªº²Ó­M¡B¤£·l¶Ë¥¿±`²Ó­M¡F¦pªG¹ï¡uCAR-T¡v²Ó­Mªº³]­p©Î¬O®Ä¥Îµû¦ô¨S¦³±±¨î¦n¡A´N·|²£¥Í°Æ§@¥Î¡C¥L©Z¨¥¡A¡uCAR-T¡v¤£¬O·s§Þ³N¡A¦bªvÀø¸~½F¤è­±¤w±q²Ä¤@¥N§ó·s¨ì²Ä¤T¥N¡A¤£¹L¦bªvÀø·R´þ»â°ì«h¨S¦³¦¨¼ôªºÁ{þHÀøªkÀò±oFDA§å­ã¡C³¯§Ó°¶»¡¡A¦pªGªZº~³o¨â¦W±Ð±Âªº¹êÅç¬O¯u¹ê¡B¥i¾a¥B¦³®Ä¡A¨º»ò¬ì¾Ç¬É·íµMÅwªï¡A¦ý¥L¤]ºÙ¡A¥Î¡uCAR-T¡vÀøªkªvÀø·R´þ¬Û¹ï©ù¶Q¡A¦]¬°°ö¨|¡uCAR-T¡v»Ý­n°®²bªÅ¶¡¡B¨S¦³·L¥Íª«¦Ã¬V¡A©Ò¥H¦¨¥»«Ü°ª¡C

³¯§Ó°¶¡G

Àøªk»Ý°®²bªÅ¶¡ ¦¨¥»©ù¶Q

¡mªø¦¿¤é³ø¡n¤Þ­z±i¦P¦s±Ð±ÂºÙ¡A¡u¦b¬ü°ê¡A¥ÎCAR-T§Þ³NªvÀø¸~½Fªº¶O¥Î¬ù47.5¸U¬üª÷¡AªvÀø·R´þ¯fªº¶O¥Î¥i¶i¦æ°Ñ·Ó¡A¦ý¦pªGCAR-T§K¬Ì²Ó­MªvÀø·R´þ¯f§Þ³N¦b¤¤°êµo®i¦¨¼ô¤F¡A¶O¥Î±N¤j¤j­°§C¡C¡v¦­«e­»´ä²o°Ê¤H¤ßªº17­Ó¤ë¤j¨kÀ¦±i¥i¤¯¡A¥Î§K¬ÌÀøªkªvÀø¯«¸g¥À¸~½F¡A¶O¥Î¬ù»Ý200¸U´ä¤¸¡C

§ó¦h¤¤°ê­n»D
¤¤ÃҺʭã¼W«ù ·ç»È¦¨­º®a¥~¸ê±±ªÑ¨é°Ó
¡u²ß¯S·|¡v«e¤i¡A¤¤°êÃҺʷ|©P¤­²`©]«Å¥¬¡A·ç¤hªº·ç»È¶°¹ÎÀò­ã¼W«ù¨ä¤º¦aªº¦X¸êÃҨ餽¥q·ç»ÈÃÒ¨é¡AªÑÅv¦û¤ñ±N¼W¦Ü51%¡A¦¨¬°­º®a¥Ñ¥~¸ê±±ªÑªº¹Ò¤º¨é... ¸Ô±¡
ªñ¤ë¤¤°ê¿n·¥¦V¥~¸ê¶}©ñª÷¿Ä¥«³õ¡A¦³·~¤º¤H¤hºÙ¡A¥D­n¦]¬°¦b¤¤¬ü¶T©ö¾Ôªº­I´º¤U¡A¤¤°ê­n§Q»¤¥~¸ê¥[¤j¦b¤¤°êªº§ë¸ê¡A¦P®ÉÂǦ¹»P¼Ú¸ê¥ø·~¥´¦nÃö«Y¡C³Ì­«... ¸Ô±¡
®]¨È¤Ò¡G¤@­±ª§¨ú¥xÆW¥Á¤ß¤@­±Àç³y²Î¤@Àô¹Ò
¡i©ú³ø±M°T¡j¡u¬ö©À¡y§i¥xÆW¦P­M®Ñ¡zµoªí40©P¦~¨â©¤¾Ç³N¬ã°Q·|¡v¬Q¤é¦b¤W®üµØªF®v½d¤j¾ÇÁ|¦æ¡A¤j³°®ü¨ó·|°Æ·|ªø¡B°ê¥x¿ì«e°Æ¥D¥ô®]¨È¤Òªí¥Ü¡A­n§ìºò... ¸Ô±¡
¤E¦X¤@¦X¨Ö¤½§ë¶Ã¶H¦Ê¥X
¥xÆW¤E¦X¤@¿ïÁ|³s¦P¤Q¶µ¤½§ë¦X¨Ö§ë²¼¡A¦ý¦]¬°¤¤¥¡¿ïÁ|©e­û·|¦w±Æ¤£©P¡AÅý§ë²¼¶Ã¶H¦Ê¥X¡A¤Þ°_ª§Ä³¡C³o¬O­º¦¸¦³¤½§ë¹LÃö¡A¥H®Ö¾iºñ¡B¤Ï®Ö­¹¡B¤Ï¦Pµ¥Ä³ÃD... ¸Ô±¡
­x¤½±Ð¡u©]ŧ¡vºñÀç
¦~ª÷§ï­²¦¨¬°°ª¶¯°fÂà°õ¬FÅvªº³Ì«á¤@®Ú½_¯ó °ª¶¯¦]ª«»ù¡B©Ð»ù¸û¥x¥_«K©y¡A¦¨¬°¤£¤Ö°h¥ð¤H¤hªº»E©~¦a¡A·í¤¤¦³«Ü¦h¬O­x¤½±Ðªº¦¨­û¡C·í¥Á¶i... ¸Ô±¡

©ú³øºô¯¸ ¡P ª©Åv©Ò¦³ ¡P ¤£±oÂà¸ü
Copyright © 2016 mingpaocanada.com All rights reserved.
Ming Pao Daily News A wholly owned subsidiary of Ming Pao Enterprise Corporation Ltd.
Vancouver Chinese Newspaper

5368 Parkwood Place, Richmond B.C. V6V 2N1 | Tel.: (604) 231-8998 | Fax: (604) 231-9881/9884 | Advertising Hotline Tel.: (604) 231-8992